Immuno Oncology Assays Market Snapshot
“The Immuno Oncology Assays Market is estimated to increase at a CAGR of 11.14% from $ 6.74 billion in 2023 to $ 11.67 billion by 2030.”
Next-generation sequencing applications include immuno oncology tests, which maintain cell morphology and health for real-time measurements or continuous analysis. Examples include tumor killing assays, T cell assays, tumour cell assays, natural killer cell assays, macrophage assays, and dendritic cell assays.
High-throughput platform research aids oncology and immunotherapy research by studying immune cell regulation, including cell activation, proliferation, fatigue, chemotaxis, and cytokine response. Assays offer methods for studying immune cell population changes and can be expanded for in vivo studies with CAR-T, immune-checkpoint inhibitors, and other immune-modulators.
Axion's live-cell analysis tools can streamline immuno-oncology research by assessing potential candidates quickly and effectively. These tools can help speed up the development of life-saving medicines targeting and destroying tumours using the body's immune system. They can also help in exploring immunomodulators and measuring CAR cell death in solid and liquid tumors.
The global immuno-oncology tests market is expanding rapidly due to rising cancer burdens and a focus on innovative treatments. However, challenges like a shortage of qualified specialists and an unfriendly regulatory environment are expected to hinder the market's growth, hindering its growth.
>>>Download Sample Report Now: https://marketreportservice.com/request-sample/immuno-oncology-assays-market-54645
Market Dynamics
Growth Drivers
The global immuno-oncology tests market is expanding rapidly due to rising cancer burdens and a focus on innovative treatments. However, challenges like a shortage of qualified specialists and an unfriendly regulatory environment are expected to hinder the market's growth, hindering its growth.
The global immuno-oncology tests market is expected to grow due to the growing focus on discovering innovative cancer treatments. Immuno-oncology involves using the body's immune system to target and destroy cancer cells, aiming for precision cancer treatment. Researchers are exploring novel cancer-fighting strategies in this field.
- burden of cancer is increasing rapidly.
- The focus is shifting towards the development of innovative cancer treatments.
Restraints
- shortage of skilled professionals.
- The situation is currently unfavorable in terms of regulatory and reimbursement policies.
Opportunities
The global immuno-oncology assays market is expected to see growth opportunities due to increased R&D activities. Singapore's first integrated translational R&D hub, established in 2019, uses biochemical innovation and research data analytics to develop new diagnostic methods.
Agilent Technologies received approval from the South Korea Ministry of Food and Drug Safety in June 2022 for its PD-L1 IHC 22C3 pharmDx, a companion diagnostic for identifying patients with NSCLC, suitable for first-line monotherapy with KEYTRUDA.
Immuno Oncology Assays Market Segment Analysis
The immunoassay segment is predicted to dominate the market due to its ability to measure the presence and concentration of large proteins and antibodies produced by cancer patients. The segment's growth is driven by the increased cancer burden, new product approvals, and launches by leading players, contributing to its significant market share.
The immuno-oncology tests market, categorized into immunoassay, PCR, NGS, Flow Cytometry, and others, is expected to dominate due to rising cancer incidence globally, primarily used in pharmaceutical, drug research, and disease diagnosis sectors.
The Lung Cancer Research Foundation predicts that by 2022, 236,740 US individuals will be diagnosed with lung cancer, with 1 in every 16 diagnosed throughout their lifetime. The research suggests that immunoassays will be crucial for accurately identifying cancer, enhancing care and reducing the burden of cancer patients.
New product approvals and launches, such as Nonagen Bioscience's Oncuria immunoassay for bladder cancer, contribute to market growth. The multiplex urine test detects 10 biomarkers linked to bladder cancer, indicating significant growth in the segment over the forecast period.
Immuno-oncology, the study and development of cancer treatments using the body's immune system, is expanding due to the rise in cancer incidence. The European cancer burden is expected to reach 3.36 million new cases by 2040, and the increasing use of targeted therapy is driving market expansion. Assays determine therapeutic antibodies, anti-drug antibodies, and soluble protein biomarkers, the market for tests also grows.
Competitive Landscape of the Immuno Oncology Assays Market Analysis
New Developments in Immuno Oncology Assays Market
Oct. 04, 2023, QIAGEN launches QuantiFERON-EBV RUO assay, facilitating research of cell-mediated immune response to Epstein-Barr virus
QIAGEN announced the launch of its QuantiFERON-EBV RUO (Research Use Only) assay. Epstein-Barr virus (EBV), or human herpes virus 4, is estimated in various epidemiological studies to be positive in more than 90% of the world’s population and is a significant pathogen in organ transplant recipients.
March 15, 2022, Illumina Unveils Groundbreaking Comprehensive Genomic Profiling Test for Cancer in Europe
Illumina, Inc. announced the launch of TruSight™ Oncology (TSO) Comprehensive (EU), a single test that assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer. With its global launch first taking place in Europe, the in vitro diagnostic (IVD) kit will help inform precision medicine decisions for cancer patients across the continent.
24-Jan-2023 Charles River Laboratories, Inc - Make or Break: Immuno-Oncology Therapeutic Strategies to Overcome T Cell Exhaustion
Our recent virtual immuno-oncology symposium featured a panel of experts highlighting developments in immuno-oncology with a focus on T cell exhaustion in response and resistance to treatment. Several topics were covered providing a comprehensive overview of the emerging trends to improve the efficacy and duration of response to immuno-oncology therapies. In case you missed the presentations they are now available on-demand below.
Regional Outlook
North America is expected to experience strong growth due to the presence of prominent companies, high cancer frequency in the region, and developed healthcare infrastructure. Government initiatives and research alliances are expected to support market expansion. The National Institutes of Health predicts 1,918,030 new cancer cases by the end of 2022, while Health Canada predicts 233,900 Canadians will be diagnosed with cancer in June 2022, with 85,100 dying.
Agilent Technologies Inc.'s Ki-67 IHC MIB-1 pharmDx, approved by the FDA in October 2021, aids in identifying patients with early breast cancer at high risk of recurrence. This tool is ideal for patients considering adjuvant treatment with Verzenio in combination with endocrine therapy. New immune-oncology assay methodologies broaden usage, driving market expansion in North America during the forecast period.
Asia Pacific is expected to remain the fastest-growing market for immuno-oncology assay launches due to increased acceptance of targeted therapy, rising cancer incidence, and population growth. The World Health Organisation reports that developing countries have two to three times more ICU-acquired infections than developed ones.
Segments Covered in the Immuno Oncology Assays Market Report
By Product
By Technology
- Immunoassay
- PCR
- NGS
- Flow Cytometry
- Others
By Indication
- Colorectal Cancer
- Lung Cancer
- Melanoma
- Bladder Cancer
- Others
By Application
- Clinical Diagnostics
- Research
The above information has been provided for the following regions and countries:
North America
Europe
- UK
- Germany
- France
- Italy
- Russia
Asia Pacific
- China
- India
- Japan
- South Korea
Latin America
MEA
- UAE
- Saudi Arabia
- South Africa
Frequently Asked Questions
What is the expected growth rate of the Immuno Oncology Assays market over the next 7 years?
The Immuno Oncology Assays Market is estimated to increase at a CAGR of 11.14% from $ 6.74 billion in 2023 to $ 11.67 billion by 2030.
Who are the major players in the Immuno Oncology Assays market and what is their market share?
Illumina, Inc.,Qiagen Nv.,Charles River Laboratories, Inc.,F. Hoffmann-La Roche Ltd.,Agilent Technologies, Inc.,Nanostring Technologies, Inc.,Perkinelmer, Inc.,Bio-Rad Laboratories, Inc.,Thermo Fisher Scientific, Inc.,Sartorius Ag, are prominent players operating and dominating in the market.
What is the demand projection for Immuno Oncology Assays by 2030?
Demand for Immuno Oncology Assays is projected to reach a market value of US$ 11.67 billion by 2030-end.
What is the sales growth projection for Immuno Oncology Assays?
Revenue from sales of Immuno Oncology Assays is projected to increase at a CAGR of 11.14% through 2030.
1.SUMMARY
1.1. Immuno Oncology Assays Market Overview
1.2. Key Insights
1.3. Report Scope
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
- DECISION-MAKING SUMMARY
- INTRODUCTION
3.1. Overview of Immuno Oncology Assays
3.2. Key Historical Events
3.3. Structure
3.4. Biochemical Interaction
3.5. Target Indications
3.6. Advantages of Immuno Oncology Assays
3.7 Challenges associated with Immuno Oncology Assays
3.8. Future Perspectives.
- MARKET LANDSCAPE
4.1. Methodology
4.2 Immuno Oncology Assays: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters (Region-wise)
4.2.4. Analysis by Location of Headquarters (Country-wise)
4.2.5. Analysis by Year of Establishment, Company Size and Location of Headquarters (Region-wise)
4.2.6. Most Active Players
- COMPANY
5.1. Company Overview
5.1.2 Management Team
5.1.3. Product Portfolio
5.1.4. Recent Developments and Future Outlook
- PARTNERSHIPS AND COLLABORATIONS
6.1. Partnership Models
6.2. Immuno Oncology Assays: Partnerships and Collaborations
6.2.1. Analysis by Year of Partnership
6.2.2. Analysis by Type of Partnership
6.2.3. Analysis by Year and Type of Partnership
6.2.4. Analysis by Type of Partner
6.2.5. Analysis by Year of Partnership and Type of Partner
6.2.6. Analysis by Type of Partnership and Type of Partner
6.2.7. Analysis by Type of Partner and Parent Company Size
- ACADEMIC GRANTS ANALYSIS
7.1. Methodology and Key Parameters
7.2. Immuno Oncology Assays: Academic Grants Analysis
7.2.1. Analysis by Year of Grant Award
7.2.2. Analysis by Amount Awarded
7.2.3. Analysis by Funding Institute Center
7.2.4. Analysis by Support Period
7.2.5. Analysis by Funding Institute Center and Support Period
7.2.6. Analysis by Type of Grant Application
7.2.7. Analysis by Purpose of Grant
- PUBLICATION ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. Immuno Oncology Assays: Publication Analysis
8.2.1. Analysis by Year of Publication
8.2.2. Analysis by Type of Publication
8.2.3. Analysis by Type of Conjugate
8.2.4. Analysis by Target Indication
8.2.5. Analysis by Copyright Holder
8.2.6. Word Cloud: Emerging Focus Area
8.2.7. Most Active Publishers: Analysis by Number of Publications
- SUCCESS PROTOCOL ANALYSIS
9.1. Methodology and Key Parameters
9.2. Key Assumptions and Scoring Criteria
9.3. Success Protocol Analysis
9.4. Assessment of Approved Immuno Oncology Assays
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies
- Illumina, Inc.
- Qiagen Nv.
- Charles River Laboratories, Inc.
- Hoffmann-La Roche Ltd.
- Agilent Technologies, Inc.
- Nanostring Technologies, Inc.
- Perkinelmer, Inc.
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific, Inc.
- Sartorius Ag
